BG105664A - Use of apomophines for the treatment of organic erectile dysfunction in males - Google Patents

Use of apomophines for the treatment of organic erectile dysfunction in males

Info

Publication number
BG105664A
BG105664A BG105664A BG10566401A BG105664A BG 105664 A BG105664 A BG 105664A BG 105664 A BG105664 A BG 105664A BG 10566401 A BG10566401 A BG 10566401A BG 105664 A BG105664 A BG 105664A
Authority
BG
Bulgaria
Prior art keywords
erectile dysfunction
treatment
apomophines
males
organic erectile
Prior art date
Application number
BG105664A
Other languages
Bulgarian (bg)
English (en)
Inventor
Karen Kling
Renee PERDOK
Dustin RUFF
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG105664A publication Critical patent/BG105664A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BG105664A 1998-12-17 2001-07-03 Use of apomophines for the treatment of organic erectile dysfunction in males BG105664A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/213,567 US6291471B1 (en) 1998-12-17 1998-12-17 Use of apomorphine for the treatment of organic erectile dysfunction in males
PCT/US1999/029449 WO2000035457A1 (en) 1998-12-17 1999-12-13 Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males

Publications (1)

Publication Number Publication Date
BG105664A true BG105664A (en) 2002-02-28

Family

ID=22795606

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105664A BG105664A (en) 1998-12-17 2001-07-03 Use of apomophines for the treatment of organic erectile dysfunction in males

Country Status (22)

Country Link
US (1) US6291471B1 (pl)
EP (1) EP1140094A1 (pl)
JP (1) JP2003521462A (pl)
KR (1) KR20010101241A (pl)
CN (1) CN1335772A (pl)
AR (1) AR021912A1 (pl)
AU (1) AU2175800A (pl)
BG (1) BG105664A (pl)
BR (1) BR9916114A (pl)
CA (1) CA2354601A1 (pl)
CZ (1) CZ20012084A3 (pl)
HK (1) HK1043303A1 (pl)
HU (1) HUP0201618A3 (pl)
IL (1) IL143410A0 (pl)
NO (1) NO20012985L (pl)
NZ (1) NZ511790A (pl)
PL (1) PL354920A1 (pl)
SK (1) SK8262001A3 (pl)
TR (1) TR200101719T2 (pl)
TW (1) TW577740B (pl)
WO (1) WO2000035457A1 (pl)
ZA (1) ZA200104146B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
MXPA03004547A (es) * 2000-11-22 2004-03-26 Abbott Lab Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual.
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7648995B2 (en) 2004-04-13 2010-01-19 The Mclean Hospital Corporation R(—)-11-hydroxyaporphine derivatives and uses thereof
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
WO2009009083A1 (en) * 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
WO2014170383A1 (en) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2016174155A1 (en) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3807897A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
EP0865789B1 (en) 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle

Also Published As

Publication number Publication date
NO20012985D0 (no) 2001-06-15
AR021912A1 (es) 2002-09-04
BR9916114A (pt) 2003-01-14
SK8262001A3 (en) 2002-01-07
HUP0201618A3 (en) 2003-03-28
US6291471B1 (en) 2001-09-18
TR200101719T2 (tr) 2002-08-21
NO20012985L (no) 2001-08-16
EP1140094A1 (en) 2001-10-10
CN1335772A (zh) 2002-02-13
HUP0201618A2 (en) 2002-09-28
ZA200104146B (en) 2002-08-21
CA2354601A1 (en) 2000-06-22
CZ20012084A3 (cs) 2002-01-16
KR20010101241A (ko) 2001-11-14
TW577740B (en) 2004-03-01
WO2000035457A1 (en) 2000-06-22
AU2175800A (en) 2000-07-03
IL143410A0 (en) 2002-04-21
HK1043303A1 (zh) 2002-09-13
PL354920A1 (pl) 2004-03-22
NZ511790A (en) 2004-04-30
JP2003521462A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
MY119375A (en) Treatment of tinnitus using neuroprotective agents
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HK1091418A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
BR9911060A (pt) Composições compreendendo mono- ou dinitrato orgânico para tratar impotência
UA41355C2 (uk) Засіб для лікування нейро-сніду
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
IL143985A0 (en) New use of melagatran
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
TW200517118A (en) Anti tumor agent
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
NO304011B1 (no) Anvendelse av atipamezol til fremstilling av et medisinsk preparat for behandling av menns impotens
ZA200006375B (en) Compounds for the treatment of female sexual dysfunction.